{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-039900","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.353848+00:00","generated_at":"2026-06-08T09:55:12.723105+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lantern Pharma Q3 net loss $3.2M ($0.29/shr); cash $44.9M; LP-284 IND cleared, LP-184 dosed first patient","bullets":["Net loss $3.2M ($0.29/shr) vs $2.3M ($0.21/shr) in Q3 2022; R&D rose to $2.2M from $0.7M due to prior-year one-time payment.","Cash, equivalents, and marketable securities $44.9M at Sep 30 vs $55.2M at Dec 31; runway into at least Q3 2025.","Received FDA IND clearance for LP-284 Phase 1 trial in refractory non-Hodgkin's lymphomas; dosed first patient in LP-184 Phase 1 solid tumor basket trial.","RADR AI platform surpassed 36B oncology datapoints; new modules for ADC design, BBB permeability prediction, and IO combination therapy.","Phase 2 Harmonic trial of LP-300 in never-smoker NSCLC expanded to additional U.S. sites and Asia; Dr. Joseph Treat named lead PI."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-039900","json":"https://secwatch.observer/filing/0001493152-23-039900.json","markdown":"https://secwatch.observer/filing/0001493152-23-039900.md","text":"https://secwatch.observer/filing/0001493152-23-039900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315223039900/0001493152-23-039900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315223039900/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T09:55:12.723105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0dee1445a5a724809fa67ceb7539df0be39bdc8e","claim":"Lantern Pharma Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 8, 2023, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315223039900/0001493152-23-039900-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}